Dr. Clay Siegall is the CEO and Founder of Seattle Genetics. He founded the Seattle-based biotech in 1998. The firm is focused on developing therapeutic drugs for chronic illnesses that have not experienced improvement in mortality for several years. Dr. Clay has grown Seattle from a group of few researchers to a big firm dealing with cancers related sicknesses. He believes that the contributions that are being made by Seattle will replace old cancer treatment methods like systematic chemotherapies.
Dr. Clay Siegall talked about how he has overcome challenges in his profession in an interview. When asked about how he started the business He said that he wanted to bring a better treatment for cancer patients. He witnessed people face brutal medical procedures all to do away with cancer.
Seattle makes a profit by selling their products, ADCETRICS is one of the drugs that they make a lot of sales from. They also make revenue from licensing technologies that they produce and from production partnership. Dr. Clay says that he penetrated the market by bringing to board qualified salespeople who understood the product. The drugs were also high quality, and they didn’t need to spend a lot of time adverting. The business has all along been generating new businesses by negotiating with prospective customers.
About Dr. Clay Siegall
Dr. Clay received a B.S in Zoology from the University of Maryland and proceeded to George Washington University where he received his PH.D. in Genetics. He worked for Bristol-Myers Squibb Pharmaceutical Research Institute for two years before moving to National Institute of Health and National Cancer Institute.
He developed Seattle in 1998. His agenda was to help the patients by carrying out rigorous research and performing scientific innovations. He collaborated with Takeda Pharmaceutical Company to produce ADCETRIS a drug that has been approved by more than 65 countries.
He serves on Boards of Directors of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. He has been honored by several awards with include University of Maryland Alumnus of the Year for Math, Natural Sciences, and Computer which he received in 2013. Dr. Clay has also developed a working relationship with drug manufacturers such as Genentech, Pfizer, and Bayer among others.